AbCellera Biologics heads into its Monday earnings report with a setup that hasn't changed much since Friday's preview: short interest remains deeply dug in, the stock has just posted a sharp weekly rally, and analysts are quietly lifting their numbers — all ahead of a print that history suggests could move the stock meaningfully in either direction.
The short position here is the defining feature of the tape. At 15.2% of the free float — roughly 45.5 million shares — bears have not flinched despite the 21% weekly rally that carried ABCL to $6.93. Short interest ticked up just over 2% in the past month and barely moved this week, a signal that conviction on the short side has not eroded. The ORTEX short score has held above 77 through the entire move, placing the stock in elevated crowding territory. That matters because it suggests pressure could build fast in either direction post-earnings.
The lending market is less alarming than the short interest level alone might imply. Borrow availability has nearly tripled over the past week to 83%, loosening sharply from the tight end of the range seen earlier in the summer, when availability dipped to single digits. Cost to borrow is running around 6% — elevated for a biotech of this size, but not the kind of extreme that signals an imminent mechanically forced squeeze. The options market is similarly measured: the put/call ratio of 0.38 sits just above its 20-day average and well below the 52-week high of 0.63, meaning options traders are not pricing in unusual downside risk ahead of the print.
Analyst sentiment has clearly shifted. Two target raises landed within hours of the prior quarterly result — Stifel moved from $8 to $9 while maintaining Buy, and Cantor Fitzgerald lifted from $11 to $12 on an Overweight. The consensus target of $10.63 implies roughly 53% upside from current levels, a gap that reflects both the genuine optionality in AbCellera's discovery platform and the market's persistent scepticism about the timeline to monetisation. The bull case rests on a deepening partnership pipeline and early clinical progress; the bear case is a familiar one for platform biotechs — long runways, limited near-term revenue visibility, and a first-mover advantage that has yet to translate into durable earnings power.
Insiders have been buyers, not sellers, through the stock's multi-year decline. CEO and founder Carl Hansen bought nearly $580,000 worth of shares in February near $3.27, and CFO Andrew Booth added alongside him. Director John Montalbano has made multiple open-market purchases across 2025 and 2026. The pattern is consistent and repeated, though the trades are modest in scale relative to the company. Baker Bros. Advisors, a healthcare-specialist fund that rarely takes passive positions, holds nearly 10% of shares and added aggressively in the most recent reported quarter — a holder worth watching as the earnings narrative develops.
ABCL's two most recent quarterly prints produced a 7.2% next-day gain and a 2.9% gain respectively — both positive, but neither outsized. The Monday report is the first genuine test of whether the 21% weekly rally reflects durable sentiment change or simply a short-covering-fuelled squeeze ahead of an uncertain print.
See the live data behind this article on ORTEX.
Open ABCL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
